BPC-157 Side Effects: Delayed-Onset Adverse Events Explained

The three adverse-event reports FDA found

FDA's search of its adverse-event database through December 4, 2025 returned 3 reports, all concerning injectable BPC-157 [1]:

• Injection-site redness and swelling lasting 9 days. The patient was also using compounded thymosin.
• Shortness of breath leading to an emergency room visit. FDA recorded no other detail.
• Widespread skin and gum darkening that returned when the person was exposed again to a BPC-157 plus TB-500 product sold for research use.

FDA said it cannot tell whether BPC-157 caused any of these events [1]. The reports as FDA described them give no time to onset, so they do not show a delayed pattern either way.

What the small human studies measured

One chart review at a Florida clinic phoned 16 of 17 patients who had BPC-157 injected into the knee, most of them 6 months to 1 year earlier. No adverse events were noted, but the review had no control group, no validated outcome tools and relied on recalled results [2]. A pilot injected 10 mg around the bladder wall in 12 women in a single procedure and reported no adverse events [3]. A two-person pilot gave 10 mg intravenously on day 1 and 20 mg on day 2, with no measurable change in tested heart, liver, kidney, thyroid or glucose markers and no side effects reported; nothing in that design looks past day 3 [4].

FDA noted no serious adverse events in the small studies it reviewed, but called them short and small and said they gave limited safety information [1]. A 2026 systematic review of the orthopaedic and regenerative evidence found 3 studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low [6].

What the 28-day animal studies showed

The longest animal toxicity work FDA reviewed was 28 days of intramuscular dosing. In those studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels [1]. Longer studies and cancer-risk studies were not available [1]. A short-term laboratory finding in animals is a flag, not an observation in people.

Route and approval status

FDA found no human studies of BPC-157 taken by mouth, injected under the skin, used as a nasal spray or applied to the skin, and no human pharmacokinetic data for those routes [1]. BPC-157 is not an FDA-approved drug, and no FDA-approved product contains it [1].